Zytiga

Type: Product
Name: Zytiga
First reported Oct 29 2014 - Updated Oct 29 2014 - 1 reports

Delivering a patient-centred high-quality homecare prostate cancer service

The cancer team at Plymouth Hospital NHS Trust (PHNT) aims to provide the best possible standards of cancer treatment, care and support to the patients they serve. In addition to overcoming capacity issues, developing a homecare prostate cancer service ... [Published Nursing Times - Oct 29 2014]
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

How NICE can get innovative cancer meds into NHS

The National Institute for Health and Care Excellence is making progress in improving access to new cancer treatments but it needs to take proper account of true innovation and be more flexible on price for genuine game-changers.That is the view of Paul ... [Published Pharma Times - Oct 24 2014]
Entities: Paul Workman, Cancer, NHS
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

3 Drugs Critical to Johnson & Johnson's Future

Source: Johnson & JohnsonJohnson & Johnson ( NYSE: JNJ     ) is one of the planet's largest companies with operations that stretch from consumer goods to medical devices, but it's drug business growth has led to J&J's climbing sales.In the past year, ... [Published Motley Fool Discussion Boards - Oct 21 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Johnson & Johnson's net earnings up by 59% in Q3

Johnson & Johnson's net earnings has taken quantum jump of 59 per cent during the third quarter ended September 2014 and touched to $4,749 million as against $2,982 million in the corresponding period of last year. Its worldwide sales of pharmaceutical, ... [Published PharmaBiz - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Dendreon's Provenge too expensive for NHS use, says NICE

Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer on the National Health Service in England, cost regulators have ruled.In preliminary draft guidelines out this morning, the National ... [Published Pharma Times - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'

Johnson & Johnson's (NYSE: JNJ) new hepatitis C drug Olysio helped it beat third quarter Street views, but an analyst cautioned the product may have hit a high water mark.Gilead Sciences, Inc. (NASDAQ: GILD) obtained approval this week for its competing ... [Published Benzinga.com - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

J&J ups 2014 outlook again on strong Q3

Johnson & Johnson has reported a 5.1% leap in third-quarter sales to $18.47 billion, as a solid performance by its pharmaceuticals segment helped the firm beat expectations on the street.At $8.3 billion, the group’s global pharma sales were 18.1% higher ... [Published Pharma Times - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Johnson & Johnson Quarterly Profit Rises on Sale of Unit

Johnson & Johnson (JNJ) , the world’sbiggest maker of health-care products, said third-quarter profitsoared on the sale of its Ortho Clinical Diagnostics unit. Thecompany raised its full-year forecast.Net income rose 59 percent to $4.75 billion, or $1.66 ... [Published Bloomberg - Oct 14 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is

Given the recent Ebola outbreak in West Africa, the company has accelerated the development of vaccine which may be available for human trials by early 2015. These developments suggest that Johnson & Johnson is becoming more centered around its growing ... [Published Atlanta Journal And Constitution - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Second agent shows significant benefit in mCRPC pre-chemo

Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 ... [Published Urology Times - Oct 07 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 3 reports

BTG expects strong momentum to continue in second half

BTG has given a bullish outlook for its annual performance after a strong start to the year, with the specialist healthcare company entering the second half "confident of continuing this strong momentum".In spite of adverse currency exchange movements, ... [Published London South East - Oct 06 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

The Biggest Threat Facing Johnson & Johnson

In 2013, top selling immunology drug Remicade contributed $6.7 billion, or nearly a quarter of the company's pharmaceutical revenue. By 2018, when Remicade loses patent protection in the U.S., those sales could dwindle to mere fractions of what they once ... [Published Motley Fool - Oct 04 2014]

Quotes

In their discussion, Dr Hoskin and colleagues state: "Extensive use of previous docetaxel treatment (e g., more than 6 cycles) might contribute to adverse effects with radium-223; however, this possibility cannot be investigated, since cumulative docetaxel dosing data were not collected in this trial."
...us well for achieving our near-term priorities and our long-term growth drivers," said Alex Gorsky , Chairman and Chief Executive Officer. "I am proud of our colleagues around the world who are focused everyday on delivering solutions to address the evolving health care needs."
But she also stressed that "although we strongly welcome the development of new drugs for this group of men, the treatments need to be affordable for the NHS and the benefits for men need to be clear"
"The loss of Olysio sales looks to underscore the company's reliance on high-margin Pharma revenues for earnings" Purcell said in a note Wednesday

More Content

All (108) | News (95) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Delivering a patient-centred high-quality homec... [Published Nursing Times - Oct 29 2014]
AZ lines up second Cambridge blockbuster drug [Published Business Weekly UK - Oct 27 2014]
3 Biotech Stocks Growing Faster Than Gilead Sci... [Published Motley Fool Discussion Boards - Oct 27 2014]
EMA, NICE, EC News Roundup: Roche, Boehringer I... [Published Bioresearch Online - Oct 27 2014]
Coming ever closer – first PARP inhibitor on tr... [Published Cancer Research UK - Oct 24 2014]
Sequencing Radium-223 and Docetaxel in Prostate... [Published General Medicine eJournal - Oct 24 2014]
How NICE can get innovative cancer meds into NHS [Published Pharma Times - Oct 24 2014]
Johnson & Johnson Share price: Healthcare Arist... [Published Invezz - Oct 24 2014]
NICE Says Dendreon’s Prostate Cancer Drug Is To... [Published FDA News - Oct 23 2014]
Johnson & Johnson : Reports 2014 Third-Quarter ... [Published 4 Traders - Oct 22 2014]
Is Johnson & Johnson's Worst Nightmare Becoming... [Published Motley Fool Discussion Boards - Oct 22 2014]
Innocrin Pharmaceuticals Created as a Spin-out ... [Published Town Hall - Oct 22 2014]
3 Drugs Critical to Johnson & Johnson's Future [Published Motley Fool Discussion Boards - Oct 21 2014]
Welsh Cancer Plan: health boards 'must be held ... [Published Pharma Times - Oct 19 2014]
Recent Purchase: Johnson & Johnson [Published Seeking Alpha - Oct 17 2014]
Johnson & Johnson's net earnings up by 59% in Q3 [Published PharmaBiz - Oct 17 2014]
NICE not recommending Dendreon cancer vaccine [Published Pharmafocus - Oct 16 2014]
Dendreon's Provenge too expensive for NHS use, ... [Published Pharma Times - Oct 16 2014]
Barclays: Johnson & Johnson's Q3 Could Be 'High... [Published Yahoo! Finance - Oct 15 2014]
Barclays: Johnson & Johnson's Q3 Could Be 'High... [Published Benzinga.com - Oct 15 2014]
Johnson and Johnson Reports Upbeat Q3 Earnings [Published Bidness Etc - Oct 15 2014]
Questions raised on longevity of Olysio driving... [Published PMLive - Oct 15 2014]
Hep. C medication boosts J&J earnings [Published Medical Marketing And Media - Oct 14 2014]
Why I’m in Johnson & Johnson for the long run [Published Globe and Mail - Oct 14 2014]
Johnson & Johnson third-qtr results beat analys... [Published Pharma Letter - Oct 14 2014]
JOHNSON & JOHNSON : J&J beats forecasts, helped... [Published 4 Traders - Oct 14 2014]
J&J ups 2014 outlook again on strong Q3 [Published Pharma Times - Oct 14 2014]
UPDATE 2-J&J beats forecasts, helped by hepatit... [Published CNBC - Oct 14 2014]
3 Dividend Stocks to Buy If the Market Crashes [Published Motley Fool - Oct 14 2014]
Johnson & Johnson Lifts Outlook Again As Q3 Res... [Published RTTNews.com - Oct 14 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Futures Euphoria Deflated By Latest Batch Of Ug... [Published Zero Hedge - Oct 14 2014]
So far the overnight session has been a mirror image of Monday's, when futures languished at the lows only to ramp higher as soon as Europe started BTFD. Today, on the other hand, we had a rather amusing surge in the AUDJPY as several central banks were ...
Janssen reports Phase 3 COU-AA-302 trial result... [Published PBR - News - Sep 29 2014]
Janssen-Cilag International NV today announced that data from a final analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo ...
ZYTIGA® Plus Prednisone Demonstrates Statistica... [Published PR Newswire: Policy & Public Interest - Sep 28 2014]
HORSHAM, Pa., Sept. 28, 2014 /PRNewswire/ -- A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone ...
ZYTIGA® Plus Prednisone Demonstrates Statistica... [Published Business Wire Photo/Multimedia News - Sep 28 2014]
BEERSE, Belgium--(BUSINESS WIRE)--ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...
ZYTIGA® Plus Prednisone Demonstrates Statistica... [Published Business Wire Health News - Sep 28 2014]
BEERSE, Belgium--(BUSINESS WIRE)--ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.